Article
Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors.
Oncotarget - 24 May 2016
Rossi Sabrina, Sbaraglia Marta, Dell'Orto Marta Campo, Gasparotto Daniela, Cacciatore Matilde, Boscato Elena, Carraro Valentina, Toffolatti Luisa, Gallina Giovanna, Niero Monia, Pilozzi Emanuela, Mandolesi Alessandra, Sessa Fausto, Sonzogni Aurelio, Mancini Cristina, Mazzoleni Guido, Romeo Salvatore, Maestro Roberta, Dei Tos Angelo P
Abstract excerpt
AIM: The BRAF mutation is a rare pathogenetic alternative to KIT/PDGFRA mutation in GIST and causes Imatinib resistance. A recent description of KIT and BRAF mutations co-occurring in an untreated GIST has challenged the concept of their being mutually exclusive and may account for ab initio resistance to Imatinib, even in the presence of Imatinib-sensitive KIT mutations. BRAF sequencing is generally limited to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.